Lung Cancer Therapeutics Market Revenue 2025 to 2034
Lung Cancer Therapeutics Market Revenue 2025 to 2034
Lung Cancer Therapeutics Market (By Therapy: Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, Others; By Lung Cancer Type: Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Lung Carcinoid Tumor; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies; By Type of Molecule: Small Molecules, Biologics; By Drug Class: Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others; By Geography: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) – Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034
Customisation Request
Revenue, 2025
USD 35.37 Bn
Forecast Year, 2034
USD 71.30 Bn
CAGR, 2025 - 2034
8.10%
Report Coverage
Worldwide
Published By
Saurabh Bidwai
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
The global lung cancer therapeutics market was valued at USD 35.37 billion in 2025 and is expected to reach nearly USD 71.30 billion by 2034, expanding at a CAGR of 8.10%, driven by rising cancer prevalence, advances in targeted therapies, and growing adoption of immunotherapies.
Lung Cancer Therapeutics Market Size Analysis
Lung Cancer Therapeutics Market Size By Therapy 2025 to 2034 (USD Billion)
| Therapy | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Radiation Therapy | 6.37 | 6.86 | 7.40 | 7.97 | 8.59 | 9.26 | 9.98 | 10.76 | 11.59 | 12.50 |
| Targeted Therapy | 9.20 | 10.02 | 10.93 | 11.91 | 12.98 | 14.15 | 15.41 | 16.79 | 18.29 | 19.93 |
| Immunotherapy | 10.26 | 11.21 | 12.24 | 13.37 | 14.60 | 15.95 | 17.41 | 19.00 | 20.74 | 22.63 |
| Chemotherapy | 7.78 | 8.23 | 8.71 | 9.21 | 9.74 | 10.29 | 10.87 | 11.47 | 12.11 | 12.77 |
| Others | 1.77 | 1.91 | 2.05 | 2.21 | 2.39 | 2.57 | 2.77 | 2.99 | 3.22 | 3.47 |
Lung Cancer Therapeutics Market Size By Lung Cancer Type 2025 to 2034 (USD Billion)
| Lung Cancer Type | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Small Cell Lung Cancer | 8.49 | 9.10 | 9.75 | 10.46 | 11.21 | 12.01 | 12.87 | 13.79 | 14.77 | 15.83 |
| Non-small Cell Lung Cancer | 24.41 | 26.46 | 28.68 | 31.10 | 33.71 | 36.55 | 39.62 | 42.95 | 46.56 | 50.48 |
| Lung Carcinoid Tumor | 2.48 | 2.68 | 2.89 | 3.13 | 3.38 | 3.65 | 3.95 | 4.27 | 4.62 | 4.99 |
Lung Cancer Therapeutics Market Size By Distribution Channel 2025 to 2034 (USD Billion)
| Distribution Channel | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | 22.28 | 23.95 | 25.74 | 27.66 | 29.73 | 31.95 | 34.34 | 36.90 | 39.65 | 42.61 |
| Retail Pharmacies | 8.49 | 9.17 | 9.90 | 10.69 | 11.55 | 12.47 | 13.46 | 14.54 | 15.70 | 16.96 |
| Online Pharmacies | 4.60 | 5.12 | 5.69 | 6.33 | 7.02 | 7.79 | 8.64 | 9.57 | 10.60 | 11.73 |
Lung Cancer Therapeutics Market Size By Type of Molecule 2025 to 2034 (USD Billion)
| Type of Molecule | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Small Molecules | 20.16 | 21.68 | 23.32 | 25.09 | 26.99 | 29.03 | 31.23 | 33.60 | 36.15 | 38.89 |
| Biologics | 15.21 | 16.55 | 18.01 | 19.59 | 21.31 | 23.18 | 25.21 | 27.41 | 29.80 | 32.41 |
Lung Cancer Therapeutics Market Size By Drug Class 2025 to 2034 (USD Billion)
| Drug Class | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| Alkylating Agents | 5.31 | 5.60 | 5.90 | 6.23 | 6.56 | 6.91 | 7.28 | 7.66 | 8.05 | 8.47 |
| Antimetabolites | 4.95 | 5.33 | 5.74 | 6.18 | 6.66 | 7.17 | 7.72 | 8.31 | 8.95 | 9.64 |
| EGFR Inhibitors | 9.55 | 10.43 | 11.40 | 12.45 | 13.60 | 14.84 | 16.20 | 17.69 | 19.30 | 21.06 |
| Mitotic Inhibitors | 5.66 | 6.09 | 6.56 | 7.06 | 7.61 | 8.19 | 8.82 | 9.50 | 10.22 | 11.01 |
| Multikinase Inhibitors | 6.37 | 6.97 | 7.63 | 8.34 | 9.13 | 9.98 | 10.91 | 11.93 | 13.04 | 14.25 |
| Others | 3.54 | 3.81 | 4.10 | 4.42 | 4.75 | 5.12 | 5.51 | 5.93 | 6.39 | 6.88 |
Lung Cancer Therapeutics Market Size By Region 2025 to 2034 (USD Billion)
| Region | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | 14.50 | 15.49 | 16.55 | 17.68 | 18.88 | 20.16 | 21.53 | 22.98 | 24.54 | 26.19 |
| Europe | 9.55 | 10.30 | 11.11 | 11.99 | 12.94 | 13.96 | 15.06 | 16.25 | 17.53 | 18.91 |
| Asia-Pacific | 7.78 | 8.55 | 9.39 | 10.30 | 11.31 | 12.41 | 13.61 | 14.92 | 16.36 | 17.93 |
| Latin America | 2.12 | 2.37 | 2.63 | 2.93 | 3.26 | 3.62 | 4.02 | 4.45 | 4.93 | 5.46 |
| Middle East & Africa (MEA) | 1.41 | 1.53 | 1.65 | 1.78 | 1.92 | 2.07 | 2.23 | 2.41 | 2.60 | 2.80 |
Lung Cancer Therapeutics Market Size to Reach USD 71.30 Billion by 2034
The global lung cancer therapeutics market size was estimated at USD 35.37 billion in 2025 and is projected to be worth around USD 71.30 billion by 2034 with a CAGR of 8.10% .
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
